high mobility group nucleosomal binding domain 3Genealiases: PNAS-24 · PNAS-25 · TRIP7
Q-omics provides the consensus-scored HMGN3 profile across patient tissues and cancer cell-line models. HMGN3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, HMGN3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, HMGN3 protein abundance shows 37,366 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KICH, KIRC, and LUAD as cancer lineages where HMGN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN3 survival associations across molecular data types. HMGN3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN3 RNA expression–survival associations across cancer types. High HMGN3 expression shows unfavorable associations in KICH, ACC, LIHC, CHOL and KIRC, but favorable associations in PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for HMGN3 RNA expression.
This table summarizes HMGN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HMGN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN3 shows lower tumor expression in KICH, LUAD, BRCA and PAAD and higher tumor expression in KIRC and CHOL. The KIRC box plot shows higher HMGN3 RNA expression in tumor versus normal tissue (log2 FC = +0.750, t-test p < 0.001).
This table shows molecular features associated with HMGN3 in patient tissues and cancer cell lines. In patient samples, HMGN3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, HMGN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
